. 2022 May 16;38(3):331–337. doi: 10.1007/s12291-022-01052-w

Table 2.

Biochemical comparison between healthy control and CRC patients regarding laboratory investigations (mean ± SE)

Blood test	Healthy control participants (n = 30)	All CRC patients (n = 70)	Stage II (n = 42)	Stage III (n = 28)
Hemoglobin (g/dl)	12.48 ± 0.24	10.43 ± 0.36^*	10.77 ± 0.55^*	10.20 ± 0.47^*
Leukocytes (× 10³/mm³)	6.57 ± 0.43	8.18 ± 0.27^*	8.15 ± 0.35^*	8.24 ± 0.44^*
Platelets (× 10/mm³)	296.67 ± 11.29	287.14 ± 12.69	281.74 ± 17.27	295.25 ± 18.58
ALT (IU/L)	12.83 ± 0.79	21.34 ± 0.54^*	20.81 ± 0.76^*	22.14 ± 0.72^*
AST(IU/L)	15.27 ± 1.01	30.84 ± 0.81^*	30.52 ± 1.16^*	31.32 ± 1.06^*
T. Bilirubin(mg/dl)	0.50 ± 0.02	0.77 ± 0.03^*	0.74 ± 0.04^*	0.80 ± 0.04^*
Albumin (g/dl)	4.58 ± 0.05	3.48 ± 0.05^*	3.47 ± 0.08^*	3.44 ± 0.07^*
Urea(mg/dl)	19.87 ± 0.85	19.57 ± 0.54	18.61 ± 0.65	20.21 ± 0.78
Creatinine (mg/dl)	0.65 ± 0.02	0.95 ± 0.02^*	0.93 ± 0.02^*	0.96 ± 0.03^*
CEA(ng/ml)	0.83 ± 0.12	35.72 ± 4.82^*	35.19 ± 6.36^*	36.52 ± 7.48^*
LncRNA H-19	0.99 ± 0.02	9.90 ± 0.70^*	7.34 ± 0.40^*	13.72 ± 1.10^*
miR-200a	0.99 ± 0.01	7.58 ± 0.41^*	6.51 ± 0.32^*	9.20 ± 0.44^*

Hb Hemoglobin, ALT Alanine transaminase, AST Aspartate transaminase, CEA Carcinoembryonic antigen, LncRNA H-19 Long noncoding RNA H-19, miR-200a MicroRNA-200a, SE Standard error

*Significant from control participants (P < 0.05)